Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 94Glioma 32Brain Neoplasms 29Melanoma 21Neoplasms 17Astrocytoma 17Sarcoma, Ewing 7Ovarian Neoplasms 7Gliosarcoma 7Carcinoma, Non-Small-Cell Lung 7Neuroblastoma 6Neoplasm Metastasis 6Medulloblastoma 6Breast Neoplasms 6Sarcoma 5Recurrence 5Diffuse Intrinsic Pontine Glioma 5Small Cell Lung Carcinoma 4Rhabdomyosarcoma 4Oligodendroglioma 4Spinal Cord Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Central Nervous System Neoplasms 3Triple Negative Breast Neoplasms 2Rhabdoid Tumor 2Neuroendocrine Tumors 2Lymphoma, Follicular 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

tanespimycin 2pembrolizumab 2parsaclisib 2cemiplimab 2Midazolam 2MLN 8237 2Injections 2zanidatamab 1tislelizumab 1spartalizumab 1sitravatinib 1repaglinide 1pemigatinib 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1drospirenone 1cabiralizumab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1MLN8054 1Ipilimumab 1HMPL-013 1Gemcitabine 1Ethinyl Estradiol 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Malignancies × Temozolomide × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡